A human chondroblastoma cell line and its application

A technology of chondrocytes and tumor cells, applied in the direction of bone/connective tissue cells, animal cells, tumors/cancer cells, etc., to achieve the effect of stable tumor formation ability

Active Publication Date: 2021-08-10
SHANGHAI FIRST PEOPLES HOSPITAL
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the chondroblastoma cell line with histone H3.3K36 gene mutation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A human chondroblastoma cell line and its application
  • A human chondroblastoma cell line and its application
  • A human chondroblastoma cell line and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] 1. Establishment of cell lines

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a human chondroblastoma cell line and its application. The human chondroblastoma cell line has a deposit number of CCTCC NO: C2020110, and its donor source is a clinical histone H3.3K36M mutant chondroblastoma patient, and the 36th lysine on H3F3B is mutated to methionine Mutation of acid gene, the three-lineage differentiation of osteogenic, chondrogenic and adipogenic is blocked. It has the ability to form tumors in situ of the tibia and has stable tumorigenic ability. It can be transfected by lentivirus and has the function of gene modification. The human chondroblastoma cell line can be used for screening of drugs for the treatment of chondroblastoma, construction of a drug-resistant chondroblastoma model, construction of an animal model of chondroblastoma, screening of chondroblastoma-related biomarkers and research Mechanisms of the development of chondroblastoma. The invention provides experimental materials for researchers to deeply develop the occurrence and development mechanism of human chondroblastoma and to find or evaluate treatment plans.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a human chondroblastoma cell line and its application. Background technique [0002] Chondroblastoma (CB) is a rare benign tumor derived from chondroblasts, accounting for less than 1% of all bone tumors. It occurs more frequently in men, and most patients are between 10 and 25 years old. The ratio of male to female is about (2.0-3.0):1. More than 75% of chondroblastomas involve long bones, with the most common anatomical locations being the epiphyseal and epiphyseal regions of the distal and proximal femur, proximal tibia, and proximal humerus, with similar sites within flat bones such as the acetabulum and ilium Not uncommon; other unusual but classic sites involved are the talus, calcaneus, and patella. In the craniofacial region, the most commonly affected site is the temporal bone. Chondroblastoma almost exclusively involves a single bone and usually occurs in patients with s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12N5/09C12N5/077C12Q1/02A01K67/027C12R1/91
CPCA01K67/0271A01K2207/12A01K2227/10A01K2227/105A01K2227/106A01K2227/107A01K2227/108A01K2267/0331C12N5/0655C12N5/0693C12N2503/02G01N33/5011
Inventor 华莹奇唐玉杰蒋文艳赵克温穆浩然薛凌杭姜亚飞蔡郑东
Owner SHANGHAI FIRST PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products